Combined modality immunotherapy and chemotherapy: a new perspective

[1]  Bin Zhang,et al.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. , 2008, The Journal of clinical investigation.

[2]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[3]  M. Fishman,et al.  Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.

[4]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[5]  S. Ko,et al.  A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. , 2007, Cancer research.

[6]  J. Schlom,et al.  Cancer Vaccines: Moving Beyond Current Paradigms , 2007, Clinical Cancer Research.

[7]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[8]  L. Pease,et al.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. , 2007, Cancer research.

[9]  D. Altieri,et al.  Dendritic Cell-based Full-length Survivin Vaccine in Treatment of Experimental Tumors , 2007, Journal of immunotherapy.

[10]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[11]  Ingo Fricke,et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.

[12]  Lung-Ji Chang,et al.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. , 2006, Vaccine.

[13]  K. Black,et al.  Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination , 2006, Expert review of vaccines.

[14]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[16]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[17]  M. Morse,et al.  Combining cancer vaccines with chemotherapy , 2005, Expert opinion on pharmacotherapy.

[18]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[19]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[20]  J. Gribben,et al.  Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy , 2005, Clinical Cancer Research.

[21]  A. Bonni,et al.  Phosphorylation of BAD at Ser‐128 during mitosis and paclitaxel‐induced apoptosis , 2005, FEBS letters.

[22]  R. Li,et al.  Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim , 2005, Cell Death and Differentiation.

[23]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[24]  A. Safa,et al.  Taxol Induces Caspase-10-dependent Apoptosis* , 2004, Journal of Biological Chemistry.

[25]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[26]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[27]  E. Brambilla,et al.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma , 2003, The Journal of pathology.

[28]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[29]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[30]  J. Minna,et al.  Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification , 2002, Oncogene.

[31]  D. Munn,et al.  Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection , 2002, International journal of cancer.

[32]  B. Seliger,et al.  5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  M. Wolfson,et al.  Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent , 2002, Cell Death and Differentiation.

[34]  V. Cerundolo,et al.  Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. , 2002, Cancer immunity.

[35]  P. Krammer,et al.  Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines , 2002, International journal of cancer.

[36]  G. Giaccone,et al.  Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  D. Gabrilovich,et al.  Combination of γ‐irradiation and dendritic cell administration induces a potent antitumor response in tumor‐bearing mice: Approach to treatment of advanced stage cancer , 2001, International journal of cancer.

[38]  R. Crystal,et al.  Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. , 2001, Cancer research.

[39]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[40]  D. Cella,et al.  Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Wu,et al.  Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[42]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[43]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[44]  Ishida,et al.  Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses , 1999, Clinical and experimental immunology.

[45]  D. Longo,et al.  Bcl-2 – mediated Drug Resistance : Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes ( NFAT )-induced Fas Ligand Transcription , 1999 .

[46]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[47]  A. Fornace,et al.  Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells , 1999, Oncogene.

[48]  L. Amos,et al.  How Taxol stabilises microtubule structure. , 1999, Chemistry & biology.

[49]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[50]  J. S. Kim,et al.  CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  F. Vikhanskaya,et al.  Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. , 1998, Experimental cell research.

[52]  J. Minna,et al.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. , 1992, Oncogene.

[53]  J. Minna,et al.  Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer , 1985, The Journal of experimental medicine.

[54]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[55]  D. Gabrilovich.  Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. , 2007, The Lancet. Oncology.

[56]  Bin Yu,et al.  Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  J. Roth,et al.  An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53 , 2002, Gene Therapy.

[58]  K. Bhalla,et al.  Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. , 2001, Cancer research.

[59]  K. Schulze-Osthoff,et al.  Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. , 2001, Blood.

[60]  D. Carbone,et al.  Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  D. Longo,et al.  Bcl-2–mediated Drug Resistance: Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes (NFAT)-induced Fas Ligand Transcription , 1999 .